Navigation Links
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Date:5/6/2008

vement in patient functioning from serious to occasional impairments following initiation of RLAI (p<0.001); and 11 percent more patients reported they were "very" or "extremely" satisfied with their current antipsychotic therapy at the first visit after the initiation of treatment with RLAI compared to their first visit prior to the initiation of RLAI.

There were several limitations to the trial that preclude definitive conclusions from being made. Therefore, the results may not be generalized to other populations and additional studies will be needed to confirm this analysis.

The study was sponsored Ortho-McNeil Janssen Scientific Affairs, LLC.

About Schizophrenia

An estimated one percent of the world's population suffers from schizophrenia -- a brain disorder that impairs a person's ability to think clearly, relate to others and distinguish between reality and imagination. It typically develops in adolescence or the early twenties, although symptoms may not become immediately obvious.

About Risperidone Long-Acting Injection

Risperidone long-acting injection (RLAI) is a long-acting injectable atypical antipsychotic medication used for the treatment of schizophrenia. RLAI is marketed by Janssen-Cilag outside of the U.S. and Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. in the U.S. It is manufactured by Alkermes, Inc.

IMPORTANT SAFETY INFORMATION FOR RISPERIDONE AND RISPERIDONE LONG-ACTING INJECTION (RLAI)

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Risperidone and RLAI are not approved for the treatment of patients with dementia-related psychosis.

The most common adverse reactions observed in all clinical trials with risperidone occurring at a rate of at least 10 percent were somnolence, increased appetite, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urina
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
8. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
9. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
10. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Pharmaceuticals, a,private biotechnology company discovering and developing ... a proof-of-concept clinical trial of,SLC022 in patients ... of shingles, affects approximately 200,000 people a ... is an international, multi-center,placebo-controlled study that will ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced that ... January 12 at 8:30 a.m. EST to discuss results ... (HCV) protease inhibitor ITMN-191,(R7227) in combination with Pegasys(R) (interferon ... genotype 1. ITMN-191 is,being developed in collaboration with Roche. ...
Cached Medicine Technology:Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia 2InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191 2
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... WEIFANG, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... Company"),a leading manufacturer and distributor of high-quality, pharmaceutical ... results for the,third quarter of fiscal 2009 ended ... "The global economic environment has impacted our operations ...
... ENDO ), an innovative medical device company ... by urologists and interventional radiologists for tissue and tumor ... March 31, 2009. Highlights of the quarter include ... revenues for the first quarter of 2009 were $8.2 ...
... international thought leaders featured -SAN FRANCISCO, May 15 ... clinical trial management systems, this week hosted a constellation ... partners at its annual meeting in San Francisco. Velos ... variety of initiatives and to hear speakers from ...
... Makes Scholarship Awards Available for Top Talent in Non-Profit Sector ... ... 15, 2009 -- In recognition of the talented businesswomen in ... awards to the prestigious Menttium 100® leadership development program. , ...
... Manitoba , ... Steinbach, Manitoba, Canada (Vocus) May 15, 2009 -- Each ... Even pop singer, famed choreographer, and American Idol judge, Paula Abdul recently ... issue of Ladies Home Journal. While Abdul admits to being addicted to ...
... of a new research grant program, open to researchers from academic ... ... May 15, 2009 -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today ... researchers from academic and non-profit institutions across North America. , ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 2Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 3Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 4Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 5Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 6Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 7Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 8Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 9Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 10Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 11Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 12Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 2Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 3Health News:Menttium Offers Scholarship Award to Businesswomen Leaders 2Health News:Chronic Pain Sufferers Find Hope in the Darkness 2Health News:Exiqon Announces New Grant Program for MicroRNA Research 2
... opening to block tear drainage through the ... dry eye symptoms, and enable the eye ... tears:, Low-profile cap design virtually eliminates ... facilitates easy removal with jewelers forceps, if ...
Extended Duration absorbable plugs are designed to provide patient comfort for up to 3 months. This long lasting plug is effective and economical for transient dry eye symptoms following surgery. Ext...
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
Medicine Products: